Your browser doesn't support javascript.
loading
Niacin produces an inconsistent treatment response in the EAE model of multiple sclerosis.
Wuerch, Emily C; Mirzaei, Reza; Yong, V Wee.
Affiliation
  • Wuerch EC; Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
  • Mirzaei R; Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Yong VW; Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. Electronic address: vyong@ucalgary.ca.
J Neuroimmunol ; 394: 578421, 2024 Jul 26.
Article in En | MEDLINE | ID: mdl-39088907
ABSTRACT
Niacin was found in the lysolecithin model of multiple sclerosis (MS) to promote the phagocytic clearance of debris and enhance remyelination. Lysolecithin lesions have prominent microglia/macrophages but lack lymphocytes that populate plaques of MS or its experimental autoimmune encephalomyelitis (EAE) model. Thus, the current study assessed the efficacy of niacin in EAE. We found that niacin inconsistently affects EAE clinical score, and largely does not ameliorate neuropathology. In culture, niacin enhances phagocytosis by macrophages, but does not reduce T cell proliferation. We suggest that studies of niacin for potential remyelination in MS should include a therapeutic that targets adaptive immunity.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Neuroimmunol Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Neuroimmunol Year: 2024 Document type: Article Affiliation country: